CIGLIOLA, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 358
EU - Europa 296
Continente sconosciuto - Info sul continente non disponibili 86
AS - Asia 72
SA - Sud America 13
AF - Africa 1
Totale 826
Nazione #
US - Stati Uniti d'America 326
IT - Italia 228
RU - Federazione Russa 46
CN - Cina 28
SG - Singapore 19
CA - Canada 17
GB - Regno Unito 10
VN - Vietnam 5
BD - Bangladesh 4
BR - Brasile 4
CO - Colombia 4
AR - Argentina 3
CR - Costa Rica 3
DE - Germania 3
EE - Estonia 3
ES - Italia 3
IN - India 3
JM - Giamaica 3
JP - Giappone 3
HK - Hong Kong 2
HN - Honduras 2
MX - Messico 2
TT - Trinidad e Tobago 2
AM - Armenia 1
DK - Danimarca 1
EC - Ecuador 1
FR - Francia 1
GP - Guadalupe 1
GT - Guatemala 1
ID - Indonesia 1
IE - Irlanda 1
IQ - Iraq 1
MY - Malesia 1
NI - Nicaragua 1
PH - Filippine 1
QA - Qatar 1
SA - Arabia Saudita 1
SN - Senegal 1
TR - Turchia 1
VE - Venezuela 1
Totale 740
Città #
Ashburn 52
Milan 37
Council Bluffs 34
San Jose 24
Rome 23
North Bergen 13
Beijing 10
Singapore 10
Los Angeles 9
Naples 9
Santa Clara 8
Bologna 7
Phoenix 7
Miano 6
Moscow 6
Florence 5
Las Vegas 5
Palermo 5
Turin 5
Dallas 4
Montreal 4
New York 4
Bari 3
Cagliari 3
Chicago 3
San José 3
Brooklyn 2
Casoria 2
Catania 2
Charlotte 2
Chennai 2
Eastern Passage 2
Formigine 2
Ho Chi Minh City 2
Hong Kong 2
Jacksonville 2
Manassas 2
Newark 2
North Kansas City 2
Padua 2
Port of Spain 2
Providence 2
Queens 2
Richmond 2
San Diego 2
Taranto 2
Toronto 2
Treviso 2
Ajax 1
Allentown 1
Arapongas 1
Assisi 1
Aulla 1
Aurora 1
Avezzano 1
Baldichieri d'Asti 1
Baltimore 1
Bedford 1
Bogotá 1
Boynton Beach 1
Brampton 1
Brandon 1
Brescia 1
Brownsville 1
Cadoneghe 1
Caivano 1
Calgary 1
Cali 1
Capaccio Paestum 1
Caserta 1
Castelfranco Emilia 1
Cataguases 1
Cebu City 1
Cervinara 1
Cincinnati 1
Civitanova Marche 1
Columbus 1
Coro 1
Corona 1
Cosenza 1
Cumiana 1
Da Nang 1
Dakar 1
Dammam 1
Del Rio 1
Denver 1
Desio 1
Doha 1
Erbil 1
Fayetteville 1
Frigento 1
Frosinone 1
Fumane 1
Genoa 1
Grand Haven 1
Grand Junction 1
Guatemala City 1
Guayaquil 1
Guelph 1
Hillsborough 1
Totale 395
Nome #
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 78
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer 56
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) 48
Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials 30
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study 28
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatinbased chemotherapy before radical cystectomy (RC) 27
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer 25
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study 24
The role of androgen response pathway in association with tumor biology and response to neoadjuvant immune-checkpoint inhibitors (ICI) in muscle-invasive urothelial bladder carcinoma (MIBC) 24
Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report 24
Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy 22
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer 21
Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study 21
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer 20
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel 18
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial 16
Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center 15
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer 15
Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials 15
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study 14
Impact of age on outcomes in metastatic non–clear cell renal cell carcinoma (mnccRCC): A real-world TriNetX analysis 14
Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials 14
Targeting the Immune Checkpoint in Bladder Cancer 14
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine 13
Re: Alexander D. Sherry, Van To, Criselle D’souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024 13
Data from Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer 13
Impact of timing between neoadjuvant therapy and radical cystectomy on survival in muscle-invasive bladder cancer 13
Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions 13
Impact of Body Mass Index on Renal Function Impairment in Patients Treated for Renal Cell Carcinoma at High Risk of Recurrence: Key Implications for Systemic Therapy Eligibility 12
The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives 12
Impact of Age on Outcomes in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT) 12
AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy 12
Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy 12
Prognostic Impact of Initial Management Strategies in Metachronous Oligometastatic Renal Cell Carcinoma: A Real-World Evidence 11
The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies 11
Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis 11
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review 11
Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods 11
Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter 11
Addition of androgen-receptor pathway inhibitors to standard of care in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis 11
Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study 10
Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials 10
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer 8
Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis 7
Correction to: Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions (Current Oncology Reports, (2024), 26, 9, (977-990), 10.1007/s11912-024-01554-1) 6
Totale 826
Categoria #
all - tutte 3.184
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.184


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/2026174 0 0 0 0 17 9 4 13 52 34 27 18
2026/2027652 33 45 98 476 0 0 0 0 0 0 0 0
Totale 826